Speaker Profile

Ph.D., SVP, Research & Development and Chief Research & Development Officer, Nektar Therapeutics
Biography

Steve Doberstein leads the discovery, clinical development, and regulatory affairs teams at Nektar and joined the company in January 2010. Prior to joining Nektar, Dr. Doberstein served as Vice President of Research at XOMA, a monoclonal antibody discovery and development company, where he led the discovery and development of multiple antibody drug candidates, from discovery through non-clinical safety, translational medicine and PK/PD. Prior to that, he served as VIce President of Research at Five Prime Therapeutics, a protein and antibody discovery and development company, and Xencor, a leader in protein engineering. He also held senior leadership positions at Exelixis. He received a PhD from the Johns Hopkins University School of Medicine, and was a MDA Postodctoral Fellow at UC Berkeley. Steve also serves as the Chairman of the Board of Nektar India, and represents Nektar to the NIH Public/Private Partnership to Address the Opioid Crisis.

Presentation Title and Company Description

Immunotherapy Showcase: Supercharging the Antitumor Response: NKTR-214 and Nivolumab
Nektar Therapeutics is a research-based development stage biopharmaceutical company that discovers and develops innovative medicines in areas of high unmet medical need. Our R&D pipeline of new investigational drugs includes treatments for cancer, auto-immune disease and chronic pain. We leverage Nektar’s proprietary and proven chemistry platform in the discovery and design of our new drug candidates.

pmwc-newsletter-img

Don't Miss Important Precision Medicine Updates

PMWC is the most comprehensive precision medicine conference. To recieve the lastest news and updates from the field, subscribe to the newsletter here.

You have Successfully Subscribed!